Veracyte, Inc.
VCYT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 4.74 | 2.24 | -2.24 |
| FCF Yield | 1.57% | 0.17% | 0.15% | 0.66% |
| EV / EBITDA | 100.49 | 288.65 | 333.73 | 297.54 |
| Quality | ||||
| ROIC | 1.79% | 0.32% | 0.22% | 0.50% |
| Gross Margin | 69.22% | 68.97% | 69.46% | 62.57% |
| Cash Conversion Ratio | 2.34 | -34.29 | 0.76 | 4.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.00% | 13.39% | 14.20% | 14.55% |
| Free Cash Flow Growth | 1,099.49% | 0.00% | -82.62% | -26.47% |
| Safety | ||||
| Net Debt / EBITDA | -11.39 | -25.06 | -20.78 | -19.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.00 | 1.61 | 1.44 | 2.04 |
| Cash Conversion Cycle | 65.50 | 65.38 | 64.28 | 61.88 |